Edmonton, Canada, November 16 (ots/PRNewswire) - - Transplant Data Presented at the American Society of Nephrology Conference Isotechnika Inc. today announced results from initial data for its Phase IIb kidney transplant trial of the Company's lead immunosuppressive drug, ISA247. To date, 133 patients have been enrolled in the trial. Based on an early ...
Basel, Switzerland, November 16 (ots/PRNewswire) - - New England Journal of Medicine Article Shows no Additional Cardiac Benefit From Increasing Haemoglobin to Levels Outside Current Recommendations The long awaited results of CREATE (i), a landmark trial that investigated a key question in nephrology, were published today. CREATE set out to see if there was ...
Alderley Park, England, November 16 (ots/PRNewswire) - - First Patient Enrolled in Phase III International Randomised, Double-Blind, Placebo-Controlled Study of Vandetanib for Non-Small Cell Lung Cancer (NSCLC) After Failure of EGFR TKI Therapy AstraZeneca today announced the start of enrolment into a new Phase III study of the novel once-daily oral ...
Las Vegas, November 15 (ots/PRNewswire) - - New data confirm a five-year risk assessment tool will help ophthalmologists better predict which patients have an increased risk of developing glaucoma - Analysis finds that patients with elevated intraocular pressure (IOP) - along with other ...
Edmonton, Canada, November 15 (ots/PRNewswire) - Isotechnika Inc. will announce initial data from its Phase IIb kidney transplant trial for the Company's lead immunosuppressive drug, ISA247 on Thursday, November 16th at 8:00 a.m. ET/6:00 a.m. MT. Dr. Randall Yatscoff, Isotechnika's President & CEO, will present the initial data via web cast commencing at 9:00 a.m. ...
Glasgow, Scotland, November 15 (ots/PRNewswire) - - Also Found Compatible with Other Medicines Used by HIV/AIDS Patients A review of 17 drug-drug interaction studies involving the investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC125 was presented today as a plenary oral paper at the Eighth International Congress on Drug Therapy in HIV Infection (HIV8) in Glasgow, Scotland. The data ...
Glasgow, Scotland, November 15 (ots/PRNewswire) - - New Sub-analyses Provide Insight into Treatment Benefits New data from the combined RESIST studies (RESIST-1 and RESIST-2) show that Aptivus(R) (tipranavir), used with ritonavir (tipranavir/r) as part of combination antiretroviral therapy, continued to ...
Glasgow, Scotland, November 14 (ots/PRNewswire) - - Also Found Compatible with Other Medicines Used by HIV/AIDS Patients A review of 17 drug-drug interaction studies involving the investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC125 was presented today as a plenary oral paper at the Eighth International Congress on Drug Therapy in HIV Infection (HIV8) in Glasgow, Scotland. The data ...
Glasgow, Scotland, November 14 (ots/PRNewswire) - - Data Presented at HIV 8 Conference - New studies on the use of PREZISTA(TM), an investigational anti-HIV medication, suggest that it can be co-administered with many common medications taken by people with HIV, including other antiretrovirals, proton pump inhibitors, H2 blockers and selective serotonin reuptake inhibitors. According to current HIV ...
Glasgow, Scotland, November 13 (ots/PRNewswire) - - Patients Treated With Boosted Invirase 500 Were Significantly Less Likely to Develop Elevated Lipids Than Boosted Lopinavir Promising head to head results presented today indicate that the boosted protease inhibitor (PI/r) Invirase 500/r appears to ...
Stafford, England, November 10 (ots/PRNewswire) - To meet the volume demand from the NHS for its unique system MedifyRemote(tm), Medify Solutions (Pink Sheets - MDFY.PK) today announced that its link into the NHS now requires a PSTN link upgrade to accommodate NHS customer base user login. Whilst causing a slight delay, this activity has now been categorised by NHS BT management as a national "hot issue". BT ...
Ingelheim, Germany, November 10 (ots/PRNewswire) - - Millions of People Worldwide Living With RLS to Benefit as Treatment Becomes Globally Available Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved pramipexole, a non-ergot dopamine agonist, for the ...
Paris, November 9 (ots/PRNewswire) - - Data to be Presented at Upcoming American College of Rheumatology Annual Meeting Bristol-Myers Squibb Company (NYSE: BMY) today announced that two-year data from three Phase III pivotal trials demonstrate the long-term efficacy of abatacept in adult patients with moderate to severe rheumatoid arthritis (RA) who have ...
Calgary, Canada, November 3 (ots/PRNewswire) - - Canadian Biotechnology Company's Intellectual Property Position Strengthened by Decision TSX symbol: SBS SemBioSys Genetics Inc. (TSX: SBS), a biotechnology company developing a broad pipeline of protein-based pharmaceuticals and non-pharmaceutical ...
Toronto, Canada, November 2 (ots/PRNewswire) - EMIS, the UK's leading provider of IT systems to the primary care market is preparing to make the MedifyRemote product available across its UK customer base. Approximately 55% of all doctors in the UK currently use EMIS software each day. EMIS has been instrumental, through the NHS pilots, making sure the product not only meets customers needs but also the ...
Basel, Switzerland (ots/PRNewswire) - Seventy percent of European patients battling lung cancer had never regarded the disease as a threat prior to learning of their condition, according to results from a new pan-European public and patient survey announced on the eve of Lung Cancer Awareness Month. This ignorance about lung cancer is also indicative of a chronic ...
Kyoto, Japan (ots/PRNewswire) - - Further Therapeutic Potential of Pramipexole to be Investigated in New Disease-Modification Trial - For non-US Healthcare Media New data presented today from a meta-analysis* of nearly 1,300 Parkinson's disease (PD) patients indicate that pramipexole (Mirapexin(R) ...
Shire Pharmaceuticals Group Plc
Basingstoke, England (ots/PRNewswire) - Shire today announced the start of a new Phase IIIb clinical trial to evaluate two new dosing schedules of DYNEPO(R) (epoetin delta), the first commercial erythropoiesis-stimulating agent produced in a human cell line. DYNEPO is used in the treatment of anaemia in patients with chronic kidney disease (CKD[i]). Anaemia becomes ...
New York (ots/PRNewswire) - - Madrid, Spain Court of Appeal Confirms Pfizer's Patent Claims Pfizer Inc said today that the European Patent Office (EPO) has issued an opinion upholding, in its entirety, the company's calcium salt patent covering Lipitor. The opinion was provided at the request of a Spanish court that is hearing a patent infringement case filed against Pfizer by generic manufacturer Ranbaxy. ...
Brussels, Belgium (ots/PRNewswire) - Preliminary results from the world's most comprehensive global stroke survey are announced today by the Stroke Alliance for Europe (SAFE) and AstraZeneca (NYSE:AZN). The initial survey results point to a widespread lack of awareness of stroke. Eighty one per cent of patients and carers surveyed were not aware of stroke's ...
New York (ots/PRNewswire) - - Company Opens its Compound Library to Help Search for New Anti-Parasitic Medicines Pfizer announced today collaboration that gives access to its library of medicinal compounds -- the world's largest -- and also brings scientists from developing countries into ...
Tolochenaz, Switzerland (ots/PRNewswire) - A new study announced today by Medtronic will investigate the short and long-term benefits of adding a spinal stabilisation system to a standard herniectomy procedure in patients with spinal disc herniation. The study is the first randomised control trial to assess the ...
Berlin, Germany (ots/PRNewswire) - - Global Survey Highlights Misunderstandings About Causes and Treatment of Constipation - Not for use or publication in the USA Many people with constipation are confused about the cause of their condition and its appropriate treatment with laxatives. Results of a new large-scale global survey, announced today, show ...
Freising-Weihenstephan, Germany - (ots) - Pieris AG, a bio-pharmaceutical company developing therapeutic products comprising of Anticalins®, a novel proprietary class of human binding proteins, announced today that it has confirmed the functional antagonistic activity of its lead PRS-050 Anticalin® in vivo, supporting the development of superior biotherapeutics ...
Paris (ots/PRNewswire) - GenOdyssee S.A., a biotechnology company dedicated to the discovery of novel protein therapeutic products, has entered into a research and development cooperation agreement with Baxter AG. GenOdyssee will use its unique intellectual property position in the field of protein therapeutics, as well as its proprietary technology and integrated processes, in the discovery of novel blood clotting ...
Boston, Massachusetts and Paris (ots/PRNewswire) - KIKA Medical, a provider of advanced web-based solutions for Clinical Studies, announced the appointment of Shubh L. Sethi as Chief Operating Officer (COO). "Shubh brings unique credentials to the company at a time KIKA Medical is poised for growth on both sides of the Atlantic" said Gerard Moufflet, CEO, KIKA Medical "He has extensive experience in various markets ...
Boston, Massachusetts and Paris (ots/PRNewswire) - - KIKA Medical Will Provide Global EDC Services for One of the Largest Drug-Eluting Stent Registries in the Cardiovascular Field KIKA Medical, a provider of advanced web-based solutions for Clinical Studies, announces today that it has been selected to provide EDC services for one of the largest drug-eluting stent post-marketing registries in the ...
Vienna, Austria (ots/PRNewswire) - sanofi pasteur, [NYSE: SNY] the vaccines business of the sanofi-aventis Group, today announced that its H5N1 pre-pandemic vaccine induces antibodies that neutralize additional H5N1 circulating virus not included in the original vaccine formulation. These data, presented at the 2nd International Conference on Influenza Vaccines ...
Fukuoka, Japan (ots/PRNewswire) - - Therapy May Benefit Hypertensive Patients With Additional Risk Factors in Populations Across Asia and Latin America Single-pill amlodipine besylate/atorvastatin calcium (Caduet(R)) may reduce the 10-year risk of having a cardiovascular (CV) event - as determined by the ...
New York (ots/PRNewswire) - Pfizer said today that the Austrian Patent Office has ruled that a claim in the company's basic patent covering the use of atorvastatin, the active ingredient in Lipitor, would be infringed by generic manufacturer Ranbaxy. Ranbaxy can appeal the ruling, but the patent will remain ...